Kathlyn Stone, an associate editor, manages our health care news release review project. She tweets at @KatKStone
People who should know better are playing cat and mouse with health claims on Twitter. In the course of one week the University of Manchester used Twitter to promote two sensational health claims.
Last week evolutionary biologist Jonathan Eisen, PhD, UC-Davis, used a series of tweets to pounce on a University of Manchester promotional tweet relating to Alzheimer’s disease that he found “really disturbing.”
The original tweet claimed:
“A worldwide team of senior scientists and clinicians have come together to produce an editorial which indicates that certain microbes – a specific virus and two specific types of bacteria – are major causes of Alzheimer’s Disease.”
I asked Eisen to sum up what bugged him about the university’s tweet and how he thought it could have consequences for the news stream and public perceptions.
“The University of Manchester misrepresented the current state of knowledge about microbes and Alzheimer’s in a dangerous way,” says Eisen. “First, they did not accurately report on what was in a new editorial about Alzheimer’s and microbes. And then they added new, completely unsupported claims by one of their scientists regarding microbes supposedly being known to cause Alzheimer’s. Their misrepresentation of the state of the science is dangerous, unethical, and misleading.”
In the same week, the University of Manchester posted another sensational Tweet. This one claimed “ground-breaking results” from a breast cancer trial that made tumors “disappear” within 11 days.
“This has ground-breaking potential because it allows us to identify a group of patients who, within 11 days, have had their tumours disappear with anti-HER2 therapy alone and who potentially may not require subsequent chemotherapy. This offers the opportunity to tailor treatment for each individual woman. Professor Nigel Bundred, University of Manchester”
A story on that research published in The Telegraph – equally as staggering in its claim as the tweet – caught the attention of Alicia Staley, a breast cancer and lymphoma survivor, who linked to the story and tweeted breast cancer surgeon Deanna Attai, MD, asking: “Is this legit?”
The international criticism likely led to this statement from the lead authors urging strong caution about how the findings should be interpreted — tweeted by j.daniel Flaysakier, a French oncologist-journalist:
“We wish to emphasise that our research has shown this treatment to be suitable for a group of women with a particular type of breast cancer. We have no evidence that it would be effective for anything other than patients with newly-diagnosed, HER2 positive breast tumours. In addition, we do not yet know what effect the treatment will have on long-term survival.
“While we do not wish to downplay the significance of the findings, we also urge caution in their interpretation. Further trials will be needed before we can confirm these results, even in HER2 positive patients.”
The University of Manchester isn’t the only research institution taking to Twitter to flaunt questionable claims. Far from it. We can’t keep up with all of them while doing the bread-and butter-job of reviewing health news stories and releases. Fortunately, there are a growing number of eagle eyes looking for this stuff.
American Cancer Society director of medical communications David Sampson used Twitter to call out The Telegraph for using “astounding,” “cure,” and “breakthrough,” all in a story headline and sub-headline but neglecting to mention that the astounding study was on mice, not people. That story described research (also deemed “staggering” by The Telegraph) that took place at the Houston Methodist Research Institute while referencing the “astounding” UK research.
Attai, president of the American Society of Breast Surgeons, co-host of a long-running weekly Twitter chat on breast cancer issues (they use the hashtag #BCSM), and frequent HealthNewsReview.org contributor, has noticed a lot of misinformation going out on social media and she and other physicians, researchers and health journalists are flagging them, such as Eisen, Sampson and Flaysakier did, in an attempt to correct misleading statements.
“These press releases and media reports are very concerning — given the way that social media can quickly spread headlines and then move on to the next topic, corrections or clarifications don’t get as much attention, “ says Attai. “Really, the only safeguard (short of making these releases and stories stop) is to continue to educate the public how important it is to see beyond the hype and go to the original source.”
Staley, who is also a patient advocate and #BCSM chat co-founder, says on any given week about 1,000 people will share information and chat using the #BCSM hashtag. She said the Manchester breast cancer study “made a big splash very quickly” over social media and many from the #BCSM community reached out through direct messages asking for more information. Overall, she thinks people using social media for medical news “are much smarter now, and more skeptical than ever.” She adds:
“Too many times, the stories and breaking news that make a big splash seem to get refuted and tamped down over time. Patient advocates are very good at scanning and digesting news very quickly — and reaching out to their own personal contacts in the medical field to help determine the validity and viability of the information. When I see breaking news and stories that show major advances or miracle like “tumor melting” medicines, I know to reach out to Dr. Attai right away to check on it. I feel very comfortable sharing information — or debunking information — after I’ve checked in with Dr. Attai. I know that most patients won’t have the contacts and reach that I might have, so I feel a deep responsibility for my community to make sure that info that’s shared is accurate.”
As long as there are questionable health claims being distributed in the promotional cat-and-mouse game, there will need to be vigilant people who can hang a bell on the cat.
Comments (2)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Marc Beishon
March 18, 2016 at 8:01 amI was at the European Breast Cancer Conference when the ’11 day’ study results were announced. To be fair, the lead researchers are not given to hyperbole and the results so far from this trial are impressive, although of course there will not be survival data for a long time and also only if larger trials are done. The press release issued by the conference is reasonable I think but of course we can do without ‘ground-breaking’ etc in tweets. I think this study would make a good example of how to get a balanced news story published and not spiked… The conference release is at:
https://www.ecco-org.eu/Global/News/EBCC/EBCC10-PR/2016/03/Combination-of-lapatinib-and-trastuzumab-shrinks-HER2-positive-breast-cancer-significantly
Holly Anderson
March 21, 2016 at 7:46 amThank you for commenting on the “BREAKTHROUGH!” in Her-2/Neu positive breast cancer. Even guru advocates/MDs were reposting these stories.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like